Sean A Misek (S A Misek)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Basal Cell Carcinoma

Top Venues

International journal of cancer

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer (2024)
Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer 155 (7) (2024)
Bardees M Foda, Sean A Misek, Kathleen A Gallo, Richard R Neubig
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade. International journal of cancer (2024)
Ana S Leal, Sean A Misek, Erika M Lisabeth, Richard R Neubig, Karen T Liby
The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Scientific reports 9 (1) (2019)
Sean A Misek, K M Appleton, T S Dexheimer, E M Lisabeth, R S Lo, S D Larsen, K A Gallo, Richard R Neubig
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. Oncogene 39 (7) (2019)
Daniel P Hollern, Matthew R Swiatnicki, Jonathan P Rennhack, Sean A Misek, Brooke C Matson, Andrew McAuliff, Kathleen A Gallo, Kathleen M Caron, Eran R Andrechek
E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration. Scientific reports 9 (1) (2019)